Stacy E. Croteau, MD, MMS
Assistant Professor of Pediatrics, Harvard Medical School Director, Hemophilia/VWD Program, Boston Children's Hospital Medical Director, Boston Hemophilia Center 
Dana-Farber/Boston Children's Cancer Center & Blood Disorders Center
Boston, MA


Robert F. Sidonio, Jr, MD, MSc
Medical Director of Hemophilia Program
Director of Clinical Operations and Clinical Research
Aflac Cancer and Blood Disorders Center
Children's Healthcare of Atlanta/ Emory University
Atlanta, GA

Mark T. Reding, MD
Associate Professor of Medicine 
Division of Hematology, Oncology & Transplantation 
Director, Center for Bleeding and Clotting Disorders 
University of Minnesota Medical Center


By the end of this session, the participant should be better able to:

  • Describe the emerging therapies and novel non-factor approaches in development for treating patients with hemophilia A and B.
  • Discuss the mechanisms of action for FVIIIa mimetic bispecific antibodies and the assays needed to monitor their safety and efficacy
  • Recommend appropriate patients enroll in clinical trials for the evaluation of these therapies when and where available.